News
CLIFF
0.090
NaN%
--
Cordlife Announces Change in Company Secretaries
TipRanks · 07/15 09:58
Cordlife Shareholders Back Board and Fees at 2026 AGM
TipRanks · 05/22 12:02
Cordlife Seeks Court Conversion of Cord Blood Claims Case, Warns of Potential FY2026 Hit
TipRanks · 01/14 00:12
Cordlife Secures Renewal of Key Licences Under Continued Regulatory Constraints
TipRanks · 01/14 00:12
Cordlife Group Faces Legal Claims Over Damaged Cord Blood Units
TipRanks · 12/02/2025 14:16
Cordlife Group Announces Board Restructuring
TipRanks · 12/02/2025 13:18
Cordlife Faces Regulatory Changes in Cord Blood Banking Licence
TipRanks · 12/01/2025 13:18
Cordlife Group Announces Board Restructuring
TipRanks · 10/30/2025 13:46
Cordlife Submits Representations to MOH Amid License Suspension Concerns
TipRanks · 10/27/2025 15:12
More
Webull provides a variety of real-time CLIFF stock news. You can receive the latest news about Cordlife Group through multiple platforms. This information may help you make smarter investment decisions.
About CLIFF
Cordlife Group Limited is a Singapore-based company that owns cord blood banks across Asia, including Hong Kong, Indonesia, the Philippines, India, and Malaysia. The Company's principal activities involve investment holding and the provision of cord blood banking services. Its segments include Banking and Diagnostics. The Banking segment comprises of the banking of samples such as cord blood, cord lining and cord tissue. Cord blood, cord lining and cord tissue are collected, processed, and stored in the various laboratories. The Diagnostics segment comprises diagnostic testing such as non-invasive prenatal testing service, newborn metabolic screening, newborn genetic screening, and pediatric vision screening services. Its subsidiaries include Cordlife (Hong Kong) Limited, Cordlife Stem Cell Technology Limited, Healthbaby Biotech (Hong Kong) Co., Limited, Cordlife Technologies Pte. Ltd., CS Cell Technologies Pte. Ltd., Stemlife Berhad, and Shanghai Cordlife Biomedical Research Co., Ltd.